Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Cepheid; Enigma Diagnostics

NEW YORK (GenomeWeb News) – Cepheid said this week that it released an improved Xpert BCR-ABL Monitor test as a CE IVD product in the European Union. The firm said that the new test, which is used to monitor patients with chronic myelogenous leukemia, detects BCR-ABL chromosomal translocation in about 2 hours as compared to 2.5 hours for the original product release.


Enigma Diagnostics disclosed this week that the European Patent Office recently rejected a claim from Becton Dickinson in opposition to a patent filed by the firm. The Porton Down, England-based molecular diagnostics startup also said that the European Patent Office issued it a patent for the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies, which was at the center of the dispute with BD.

Enigma is developing a fully automated molecular diagnostics system for point-of-care testing.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.